New Strategies for the Management of Ocular Surface Disease in Glaucoma Patients

Laura Voicu; Sarwat Salim


Curr Opin Ophthalmol. 2021;32(2):134-140. 

In This Article


OSD in glaucoma patients is generally underdiagnosed and undertreated. Managing glaucoma and OSD simultaneously presents numerous challenges. While avoiding irreversible vision loss from glaucoma often takes precedence over ocular surface considerations, effective management of the ocular surface before and concomitantly with glaucoma interventions may yield better outcomes for both the surface disease and glaucoma. Recent advances in diagnostic testing, anti-inflammatory agents, and procedural interventions for OSD have been encouraging. For glaucoma, the availability of preservative-free medications, fixed-dose combination products, sustained-release delivery devices, and MIGS may reduce both the medication burden and preservative exposure and may also enhance surgical outcomes of future bleb-based surgery. Importantly, more research is necessary to better understand the multifaceted relationship between glaucoma and OSD and to gain valuable insights from evidence-based treatment algorithms for the management of these complex patients.